Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CMPS COMPASS Pathways	$3.82 -4.3%	$3.37	$2.49 ▼ $9.63	$354.01M	2.34	788,686 shs	583,172 shs
INDV Indivior	$11.56 +7.4%	$9.47	$7.33 ▼ $18.59	$1.59B	0.93	967,249 shs	1.46 million shs
OCUL Ocular Therapeutix	$7.71 -2.4%	$7.25	$4.06 ▼ $11.78	$1.23B	1.49	1.49 million shs	1.71 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+116.22%
CMPS COMPASS Pathways	+0.88%	+27.48%	+29.97%	+2.57%	-50.74%
INDV Indivior	+14.04%	+19.42%	+12.32%	-10.26%	-42.80%
OCUL Ocular Therapeutix	+0.60%	+8.07%	+4.91%	-0.88%	+70.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	2.3026 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	0.6
INDV Indivior	3.8612 of 5 stars	3.6	5.0	0.0	0.0	3.4	1.7	1.9
OCUL Ocular Therapeutix	3.4629 of 5 stars	3.4	2.0	0.0	4.1	2.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	2.00	Hold	$39.25	-1.88% Downside
CMPS COMPASS Pathways	3.00	Buy	$20.20	428.80% Upside
INDV Indivior	3.25	Buy	$15.00	29.76% Upside
OCUL Ocular Therapeutix	2.89	Moderate Buy	$16.38	112.39% Upside

Current Analyst Ratings Breakdown

Latest CMPS, INDV, OCUL, and CALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/28/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/18/2025	OCUL Ocular Therapeutix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
3/11/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
3/6/2025	INDV Indivior	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $13.00
3/4/2025	OCUL Ocular Therapeutix	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/4/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
3/4/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
2/28/2025	CMPS COMPASS Pathways	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
2/27/2025	CMPS COMPASS Pathways	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$11.00

(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$3.65 per share	N/A
INDV Indivior	$1.19B	1.34	$2.34 per share	4.94	N/A	∞
OCUL Ocular Therapeutix	$63.72M	19.24	N/A	N/A	$0.79 per share	9.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CMPS COMPASS Pathways	-$118.46M	-$2.30	N/A	N/A	N/A	N/A	-63.85%	-51.97%	5/6/2025 (Estimated)
INDV Indivior	$2M	-$0.35	N/A	6.76	N/A	-3.96%	-241.73%	15.09%	N/A
OCUL Ocular Therapeutix	-$80.74M	-$1.26	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	5/6/2025 (Estimated)

Latest CMPS, INDV, OCUL, and CALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	OCUL Ocular Therapeutix	-$0.28	N/A	N/A	N/A	$17.02 million	N/A
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million
2/27/2025	Q4 2024	CMPS COMPASS Pathways	-$0.62	-$0.63	-$0.01	-$0.63	N/A	N/A
2/20/2025	Q4 2024	INDV Indivior	$0.32	$0.32	N/A	$0.07	$262.35 million	$298.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CMPS COMPASS Pathways	0.15	8.91	8.91
INDV Indivior	N/A	0.83	0.65
OCUL Ocular Therapeutix	0.19	13.01	12.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CMPS COMPASS Pathways	46.19%
INDV Indivior	60.33%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CMPS COMPASS Pathways	4.25%
INDV Indivior	N/A
OCUL Ocular Therapeutix	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CMPS COMPASS Pathways	120	92.67 million	65.51 million	Optionable
INDV Indivior	1,164	137.88 million	N/A	Not Optionable
OCUL Ocular Therapeutix	230	159.02 million	151.71 million	Optionable

CMPS, INDV, OCUL, and CALT Headlines

Recent News About These Companies

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 5.8% - Should You Buy?

April 23 at 1:58 PM | marketbeat.com

Why Ocular Therapeutix, Inc.’s (OCUL) Stock Is Up 6.02%

April 21, 2025 | aaii.com

Geode Capital Management LLC Has $27.64 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 20, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Down 4.9% - What's Next?

April 18, 2025 | marketbeat.com

What is William Blair's Forecast for OCUL Q1 Earnings?

April 13, 2025 | marketbeat.com

Vanguard Group Inc. Purchases 99,730 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 13, 2025 | marketbeat.com

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 11, 2025 | globenewswire.com

William Blair starts Ocular Therapeutix stock with Outperform

April 10, 2025 | uk.investing.com

Ocular Therapeutix (NASDAQ:OCUL) Earns Outperform Rating from Analysts at William Blair

April 10, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLC

April 10, 2025 | marketbeat.com

Dextenza Approved for Pediatric Postop Ocular Pain/Inflammation, Allergic Conjunctivitis

April 9, 2025 | empr.com

William Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation

April 9, 2025 | msn.com

Ocular Therapeutix (OCUL) Receives a Buy from Needham

April 9, 2025 | markets.businessinsider.com

Ocular Therapeutix initiated with an Outperform at William Blair

April 8, 2025 | msn.com

Nottingham Advisors Inc. Has $835,000 Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 5, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Up 4.9% - Should You Buy?

April 4, 2025 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Trading Down 5.8% - Time to Sell?

April 3, 2025 | marketbeat.com

Raymond James Financial Inc. Makes New $1.72 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

April 2, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Recommendation of "Moderate Buy" from Analysts

April 2, 2025 | marketbeat.com

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

March 31, 2025 | globenewswire.com

Artisan Partners Limited Partnership Purchases 278,610 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

March 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS, INDV, OCUL, and CALT Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 04/24/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

COMPASS Pathways NASDAQ:CMPS

$3.82 -0.17 (-4.26%)

Closing price 04:00 PM Eastern

Extended Trading

$3.79 -0.03 (-0.79%)

As of 07:45 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Indivior NASDAQ:INDV

$11.56 +0.80 (+7.43%)

Closing price 04:00 PM Eastern

Extended Trading

$11.69 +0.13 (+1.12%)

As of 07:21 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Ocular Therapeutix NASDAQ:OCUL

$7.71 -0.19 (-2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$7.71 +0.00 (+0.01%)

As of 05:00 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time